Antitumour metastasis and the antiangiogenic and antitumour effects of a Eimeria stiedae soluble protein

Parasite Immunol. 2021 Jun;43(6):e12825. doi: 10.1111/pim.12825. Epub 2021 Feb 15.

Abstract

Some protozoa (Plasmodium falciparum, Toxoplasma gondii, etc) are used to treat cancer because they can improve tumour-induced immunosuppression. This study aims to evaluate the antitumour effect of Eimeria stiedae oocyst soluble protein (ESSP). ESSP was extracted, and mice were injected with 5 × 105 CT26 cells in the right axilla, and then, 50 μg of ESSP was intraperitoneally injected for 5 continuous days. The effect of ESSP on tumour immunity was detected by flow cytometry 25 days after the CT26 inoculation. The results showed that ESSP can inhibit the growth of CT26 subcutaneous tumours; significantly increase the expression of MHC I, MHC II, CD80 and CD86 on the surface of splenic dendritic cells; and enhance the level of IL-12 secretion. ESSP induced an increase in the number of NK cells in the mouse spleen, and the levels of IFN-γ and CD107 were upregulated in the NK cells and CD8+ T cells. The number of metastatic nodules in the lung tumours in the mice was significantly reduced, and the number of tubes, area of the loops and total length of the tubes were significantly reduced. ESSP enhances the antitumour immune response and inhibits tumour growth, metastasis and angiogenesis.

Keywords: Eimeria stiedae; CD8+ T cells; Colorectal cancer; NK cell; dendritic cells; immunotherapy; tumour metastasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Animals
  • Antineoplastic Agents / pharmacology*
  • B7-1 Antigen
  • CD8-Positive T-Lymphocytes
  • Eimeria*
  • Killer Cells, Natural
  • Mice
  • Neoplasm Metastasis / drug therapy
  • Neoplasms* / drug therapy
  • Protozoan Proteins / pharmacology*

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • B7-1 Antigen
  • Protozoan Proteins